Table 3.

Safety and bleeding results.

Significant Intracranial Hemorrhage, n (%, 95% CI)
Total	4 (6.2, 1.7–15)
Symptomatic ICH	3 (4.6, 0.9–12.9)
† Parenchymal Hematoma type-2	2 (3.1, 0.4–10.7)
Asymptomatic Intracranial Hemorrhage, n (%, 95% CI)
Parenchymal Hematoma type-1	3 (4.6, 1–12.9)
Hemorrhagic Transformation type-2	4 (6.2, 1.7–15.0)
Hemorrhagic Transformation type-1	8 (12, 5.5–22.8)
Total	15 (23, 13.5–35.2)
Other bleeding serious adverse events, n	0
Adverse Events, n	187
Serious Adverse Events, total	32
Death (brain herniation or respiratory failure), n (%)	7 (21.9)
Stroke Progression / Neurological worsening, n (%)	5 (15.6)
Significant ICH, n (%)	4 (12.5)
Cerebral Edema, n (%)	4 (12.5)
Pneumonia / Respiratory failure, n (%)	3 (9.3)
Cardiac Arrest, n (%)	3 (9.3)
Asymptomatic ICH, n (%)	2 (6.3)
* Significant laboratory abnormality, n (%)	2 (6.3)
Angioedema, n (%)	1 (3.1)
Seizure, n (%)	1 (3.1)
Definitely related to treatment	0
Probably related to treatment	3
Mortality (at discharge or Day 7), n (%)	7 (10.8)

^†One patient had a PH-2 that was also symptomatic.

^*1 patient had elevation in creatinine and liver function tests due to decreased cardiac output and 1 patient had severe hypokalemia.